Evaluation and Management of Newly Elevated Liver Enzymes

Initial Laboratory Evaluation

• The American Association for the Study of Liver Diseases recommends a comprehensive liver panel, including ALT, AST, alkaline phosphatase, total and direct bilirubin, albumin, and prothrombin time/INR, to establish a trend and confirm elevation within 2-5 days 1, 2
• Calculate R value to determine pattern of liver injury: R = (ALT/ALT ULN)/(ALP/ALP ULN), where R ≥5 indicates hepatocellular injury, R ≤2 indicates cholestatic injury, and R >2 but <5 indicates mixed injury 1
• Viral hepatitis testing, including hepatitis B (HBsAg, anti-HBc IgG, anti-HBc IgM, HBV DNA) and hepatitis C (anti-HCV, HCV RNA), should be performed 1, 3
• Autoimmune markers, such as ANA, ASMA, ANCA, p-ANCA, AMA, LKM-1, and SLA, should be evaluated 1, 2
• Additional laboratory tests, including serum acetaminophen level, alcohol markers (urinary ethyl-glucuronide, ethyl-sulfate, serum phosphatidylethanol), and creatine kinase, should be considered 1, 3, 4

Imaging Studies

• Hepatobiliary ultrasound with Doppler should be performed to assess for biliary obstruction, gallstones, portal or hepatic vein thrombosis, hepatic metastases, and fatty liver disease 1, 2, 3, 4
• Consider MRCP if cholestatic pattern is identified 1

Additional Evaluations Based on Initial Results

• Review all medications, supplements, and herbal products for potential hepatotoxicity 2, 3
• Assess for alcohol consumption history 3, 4
• Consider testing for less common viral causes, such as EBV, CMV, HSV, and VZV, if initial workup is negative 1
• Consider testing for metabolic liver diseases, such as Wilson's disease (ceruloplasmin and serum copper) and hemochromatosis (iron studies) 1, 3

Management Algorithm Based on Severity

• For ALT >300 U/L, complete workup as outlined above within 2-5 days and consider hepatology consultation if no clear cause is identified 2, 5
• If ALT continues to rise or remains persistently elevated, consider liver biopsy to determine pattern and severity of injury and non-invasive assessment of liver fibrosis (elastography, APRI, or FIB4) 1, 2, 3

Important Considerations and Pitfalls

• ALT reference ranges vary significantly between laboratories, and drug-induced liver injury is a common cause that requires careful medication review 2, 5
• Avoid attributing significant ALT elevation (>5× ULN) to NAFLD/NASH alone without ruling out other causes 4